NOT-HL-22-011: NHLBI Announces Availability of Frequently Asked Questions (FAQs) for RFA-HL-23-006, "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)"

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for RFA-HL-23-006, "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)"

Notice Number:

NOT-HL-22-011

Key Dates

Release Date:

March 4, 2022

Related Announcements

RFA-HL-23-006: Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)

NOT-HL-22-008: Notice of Correction to Eligibility Information in RFA-HL-23-006 "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)"

NOT-HL-22-009: Notice of Correction to Specific Areas of Research Interest of Participating Institutes and Centers In RFA-HL-23-006 "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)"

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that a set of responses to Frequently Asked Questions (FAQs) regarding RFA-HL-23-006 "Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)" has been posted at the following link: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/RFA-HL-23-006

Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

David Schopfer, M.D.
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-402-3833
Email: [email protected]